S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:HRMY

Harmony Biosciences (HRMY) Stock Forecast, Price & News

$34.95
-1.04 (-2.89%)
(As of 04:33 PM ET)
Compare
Today's Range
$34.91
▼
$36.49
50-Day Range
$30.50
▼
$36.59
52-Week Range
$29.81
▼
$62.08
Volume
338,001 shs
Average Volume
771,622 shs
Market Capitalization
$2.10 billion
P/E Ratio
11.27
Dividend Yield
N/A
Price Target
$62.89
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Harmony Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
79.9% Upside
$62.89 Price Target
Short Interest
Bearish
23.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.35mentions of Harmony Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
40.83%
From $2.40 to $3.38 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.02 out of 5 stars

Medical Sector

18th out of 986 stocks

Pharmaceutical Preparations Industry

8th out of 479 stocks

See Top Rated MarketRank™ Stocks Here

HRMY stock logo

About Harmony Biosciences (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HRMY Stock News Headlines

June 6, 2023 | finance.yahoo.com
HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023
June 5, 2023 | americanbankingnews.com
Analysts Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Price Target at $62.89
June 9, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
June 1, 2023 | benzinga.com
Harmony Biosciences President Awarded $4.33M Worth of Stock Options
May 30, 2023 | finance.yahoo.com
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 44th ANNUAL GLOBAL HEALTHCARE CONFERENCE
May 26, 2023 | nasdaq.com
Oppenheimer Reiterates Harmony Biosciences Holdings (HRMY) Outperform Recommendation
May 24, 2023 | seekingalpha.com
Harmony Biosciences: A Company With Solid Fundamentals (Rating Upgrade)
May 22, 2023 | markets.businessinsider.com
Harmony Biosciences Holdings (HRMY) Gets a Buy from Mizuho Securities
June 9, 2023 | Vantage Point (Ad)
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
May 12, 2023 | entrepreneur.com
Top 3 Biotech Stocks with Breakout Potential
May 11, 2023 | americanbankingnews.com
Brokerages Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Price Target at $62.89
May 10, 2023 | finance.yahoo.com
HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING
May 9, 2023 | americanbankingnews.com
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Forecasted to Post FY2023 Earnings of $2.36 Per Share
May 8, 2023 | msn.com
Harmony Biosciences Earnings Perspective: Return On Capital Employed
May 5, 2023 | americanbankingnews.com
Harmony Biosciences (NASDAQ:HRMY) PT Raised to $75.00 at Cantor Fitzgerald
May 5, 2023 | americanbankingnews.com
Harmony Biosciences (NASDAQ:HRMY) Stock Price Up 8.7% After Analyst Upgrade
May 3, 2023 | seekingalpha.com
Harmony Biosciences Non-GAAP EPS of $0.66 beats by $0.10, revenue of $119.13M beats by $2.94M
May 3, 2023 | finance.yahoo.com
Harmony Biosciences Holdings First Quarter 2023 Earnings: Beats Expectations
May 2, 2023 | finance.yahoo.com
Harmony Biosciences (HRMY) Q1 2023 Earnings Call Transcript
May 2, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Harmony Biosciences Holdings (HRMY)
May 2, 2023 | finance.yahoo.com
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q1 Earnings and Revenue Estimates
May 2, 2023 | seekingalpha.com
Harmony Biosciences Holdings, Inc. 2023 Q1 - Results - Earnings Call Presentation
May 2, 2023 | finance.yahoo.com
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
May 1, 2023 | benzinga.com
Earnings Outlook For Harmony Biosciences
May 1, 2023 | americanbankingnews.com
Harmony Biosciences (HRMY) Scheduled to Post Earnings on Tuesday
April 30, 2023 | americanbankingnews.com
FY2023 Earnings Forecast for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Issued By Cantor Fitzgerald
April 24, 2023 | finance.yahoo.com
HARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER
See More Headlines

HRMY Price History

HRMY Company Calendar

Last Earnings
5/02/2023
Today
6/09/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRMY
CUSIP
N/A
CIK
1802665
Web
www.harmonybiosciences.com
Phone
484-539-9800
Fax
N/A
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$62.89
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+75.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$3.10
Trailing P/E Ratio
11.59
Forward P/E Ratio
14.97
P/E Growth
0.53
Net Income
$181.47 million
Net Margins
40.19%
Pretax Margin
25.25%
Return on Equity
49.67%
Return on Assets
28.11%

Debt

Debt-to-Equity Ratio
0.42
Current Ratio
4.90
Quick Ratio
4.85

Sales & Book Value

Annual Sales
$437.86 million
Price / Sales
4.92
Cash Flow
$3.46 per share
Price / Cash Flow
10.38
Book Value
$6.79 per share
Price / Book
5.29

Miscellaneous

Outstanding Shares
59,960,000
Free Float
42,928,000
Market Cap
$2.15 billion
Optionable
Not Optionable
Beta
0.45

Key Executives

  • Mr. Jeffrey S. Aronin (Age 55)
    Founder & Non-Exec. Chairman
    Comp: $85k
  • Mr. John Charles Jacobs M.B.A. (Age 56)
    Pres, CEO & Director
    Comp: $885.55k
  • Mr. Sandip S. Kapadia CPA (Age 53)
    M.B.A., Exec. VP & CFO
    Comp: $717.03k
  • Dr. Jeffrey M. Dayno M.D. (Age 66)
    Exec. VP & Chief Medical Officer
    Comp: $702.74k
  • Mr. Jeffrey Dierks M.B.A.Mr. Jeffrey Dierks M.B.A. (Age 51)
    Exec. VP & Chief Commercial Officer
    Comp: $613.88k
  • Mr. Andrew Serafin J.D. (Age 48)
    M.B.A., Exec. VP & Chief Strategy Officer
    Comp: $570.92k
  • Mr. David Bradshaw
    Head of Technical Operations
  • Ms. Sharon Goldbach
    Head of Facilities Operations & Exec. Admin.
  • Luis Sanay
    Head of Investor Relations
  • Mr. Christian Ulrich
    Gen. Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













HRMY Stock - Frequently Asked Questions

Should I buy or sell Harmony Biosciences stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HRMY shares.
View HRMY analyst ratings or view top-rated stocks.

What is Harmony Biosciences' stock price forecast for 2023?

9 brokerages have issued twelve-month target prices for Harmony Biosciences' shares. Their HRMY share price forecasts range from $43.00 to $75.00. On average, they expect the company's share price to reach $62.89 in the next year. This suggests a possible upside of 75.0% from the stock's current price.
View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts.

How have HRMY shares performed in 2023?

Harmony Biosciences' stock was trading at $55.10 on January 1st, 2023. Since then, HRMY shares have decreased by 34.8% and is now trading at $35.93.
View the best growth stocks for 2023 here.

When is Harmony Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our HRMY earnings forecast.

How were Harmony Biosciences' earnings last quarter?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released its earnings results on Tuesday, May, 2nd. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.04. The firm earned $119.13 million during the quarter, compared to analysts' expectations of $118.21 million. Harmony Biosciences had a net margin of 40.19% and a trailing twelve-month return on equity of 49.67%.

What ETFs hold Harmony Biosciences' stock?

ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco S&P SmallCap Quality ETF (XSHQ) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

What other stocks do shareholders of Harmony Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

When did Harmony Biosciences IPO?

(HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

What is Harmony Biosciences' stock symbol?

Harmony Biosciences trades on the NASDAQ under the ticker symbol "HRMY."

Who are Harmony Biosciences' major shareholders?

Harmony Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (9.33%), BlackRock Inc. (8.27%), State Street Corp (1.74%), Dimensional Fund Advisors LP (1.39%), Macquarie Group Ltd. (1.38%) and Macquarie Group Ltd. (1.38%). Insiders that own company stock include Andreas Wicki, Holdings A/S Novo, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs.
View institutional ownership trends.

How do I buy shares of Harmony Biosciences?

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harmony Biosciences' stock price today?

One share of HRMY stock can currently be purchased for approximately $35.93.

How much money does Harmony Biosciences make?

Harmony Biosciences (NASDAQ:HRMY) has a market capitalization of $2.15 billion and generates $437.86 million in revenue each year. The company earns $181.47 million in net income (profit) each year or $3.10 on an earnings per share basis.

How many employees does Harmony Biosciences have?

The company employs 180 workers across the globe.

How can I contact Harmony Biosciences?

Harmony Biosciences' mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The official website for the company is www.harmonybiosciences.com. The company can be reached via phone at 484-539-9800 or via email at lcaperelli@harmonybiosciences.com.

This page (NASDAQ:HRMY) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -